CAL
PACB icon

Capital Analysts LLC’s Pacific Biosciences PACB Stock Holding History

Capital Analysts LLC’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,000
Closed -$10K – 790
2020
Q3 		$10K Hold
1,000
– – ﹤0.01% 587
2020
Q2 		$3K Hold
1,000
– – ﹤0.01% 645
2020
Q1 		$3K Buy
+1,000
New +$4.09K ﹤0.01% 620

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Capital Analysts LLC's PACB Position: Q4 2020 in Review

Capital Analysts LLC sold out of Pacific Biosciences (PACB) in Q4 2020, closing a stake of 1,000 shares — an estimated $10K sold.

Capital Analysts LLC first reported a position in PACB in Q1 2020 and held it in 3 quarters. The position peaked at $10K in Q3 2020. 210 funds tracked by Wall St. Rank hold PACB as of Q4 2020.

  • Capital Analysts LLC reported no remaining Pacific Biosciences position as of Q4 2020 after selling out during the quarter.
  • Capital Analysts LLC sold 1,000 Pacific Biosciences shares in Q4 2020, an estimated $10K.
  • Capital Analysts LLC first reported a position in Pacific Biosciences in Q1 2020 and held it in 3 quarters.
  • Capital Analysts LLC's Pacific Biosciences position peaked at $10K in Q3 2020.
  • 210 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2020.

Based on Capital Analysts LLC's 13F filing for Q4 2020, filed 16 Feb 2021.